1204975-11-0

Basic information

• Product Name: (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester
• Synonyms: (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester
• CAS NO: 1204975-11-0
• Molecular Weight: 432.525
• Mol File: 1204975-11-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester(1204975-11-0)
• EPA Substance Registry System: (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester(1204975-11-0)

Safety Data

• Hazardous Substances Data: 1204975-11-0(Hazardous Substances Data)

Usage

Description

(R)-4-(6-Benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester is a complex organic molecule characterized by a bipyrazine ring system with a methyl ester and a carboxylic acid functional group. The presence of a benzyl group and a pyridazine ring endows it with aromatic and heterocyclic properties, which may contribute to its potential applications in various fields such as pharmaceuticals or organic synthesis.

Uses

Used in Pharmaceutical Industry:
(R)-4-(6-Benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester is used as a potential pharmaceutical compound for its unique structure and functional groups, which may offer novel therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester can be utilized as a key intermediate or building block for the synthesis of other complex molecules with potential applications in various industries.
Further research and study are required to fully understand the properties and potential uses of this compound in different fields, as its unique structure and functional groups may offer new opportunities for innovation and development.

Upstream product

• 62673-31-8 benzyl(bromo)zinc 
• 34584-69-5 3,6-dichloro-4,5-dimethylpyridazine 
• 1204978-02-8 3-benzyl-6-chloro-4,5-dimethylpyridazine 
• 1204978-10-8 3-benzyl-4,5-dimethyl-6-((R)-3-methyl-piperazin-1-yl)-pyridazine 
• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 

Downstream Products

• 1204975-59-6 1-[(R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl]-ethanone 
• 1204975-42-7 LEQ-506 
• 1204976-17-9 (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid 
• 1204976-08-8 (R)-3-(5-(4-(6-benzyl-4,5-dimethylpyridazin-3-yl)-2-methylpiperazin-1-yl)pyrazin-2-yl)pentan-3-ol 

Relevant articles and documents

Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened

First disclosure: Continued optimization provided a novel type of Smoothened (Smo) antagonist based on a pyridazine core. The compound, NVP-LEQ506, currently in phaseI clinical trials, combines high intrinsic potency and good pharmacokinetic properties resulting in excellent efficacy in rodent tumor models of medulloblastoma. Activity against a Smo mutant conferring resistance observed in a previous clinical trial with a competitor compound suggests additional therapeutic potential.